Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

Vertex Pharmaceuticals has solidified its leadership in the cystic fibrosis (CF) market through strategic innovation and ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable ...

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.

Detailed price information for Vortex Energy Corp. (VRTX-CN) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...